COLO B — Coloplast A/S Balance Sheet
0.000.00%
- DKK131.97bn
 - DKK155.46bn
 - DKK27.03bn
 
- 90
 - 24
 - 13
 - 32
 
Annual balance sheet for Coloplast A/S, fiscal year end - September 30th, DKK millions except per share, conversion factor applied.
2020 September 30th  | 2021 September 30th  | R2022 September 30th  | 2023 September 30th  | 2024 September 30th  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | ARS | ARS | ARS | ARS | ARS | 
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 585 | 674 | 633 | 911 | 788 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3,514 | 3,720 | 4,659 | 5,120 | 5,550 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 6,489 | 6,994 | 8,772 | 9,937 | 10,444 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,926 | 4,386 | 5,151 | 5,979 | 6,571 | 
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 13,499 | 15,841 | 37,446 | 48,159 | 48,073 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,979 | 6,314 | 7,336 | 16,311 | 10,204 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 6,093 | 7,673 | 29,154 | 30,860 | 30,131 | 
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 7,406 | 8,168 | 8,292 | 17,299 | 17,942 | 
| Total Liabilities & Shareholders' Equity | 13,499 | 15,841 | 37,446 | 48,159 | 48,073 | 
| Total Common Shares Outstanding |